Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TASPE: Edaravone Dexborneol with rt-PA in Acute Ischemic Stroke
NCT06248242Phase 4
Key facts
- Status
- Recruiting
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Countries
- 1
- Sponsor
- The Second Hospital of Hebei Medical University
- Modality
- Small Molecules
- Drugs
- edaravone dexborneol
- Conditions
- ischemic stroke
01
Overview
Phase 4, randomised, open-label trial of edaravone dexborneol in ischemic stroke (2 arms), sponsored by The Second Hospital of Hebei Medical University. Primary endpoint: Comparison of neurological function between the two groups at Month 3. Started Jun 2021; status: recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Control Group
rt-PA + Basic Treatment
Edaravone Dexborneol Group
rt-PA + Edaravone Dexborneol
03
Who it enrols
Adult patients with acute ischemic stroke, onset < 4.5 hours, and NIHSS score >= 4. Excludes patients with history of intracranial hemorrhage, severe infection, coma, or recent major surgery.
04
Endpoints
Primary
Comparison of neurological function between the two groups
Beyond the preview
Go deeper on NCT06248242.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248242.